engage checkpoint medical linkedin twitter

The Role of PARP Inhibition in Clinical Practice

The Role of PARP Inhibition in Clinical Practice

Prof. Jonathan A. Ledermann, Dr Rebecca Dent, Dr Robert L. Coleman, Prof. Eric Pujade-Lauraine

Accredited e-learning: The Role of PARP inhibition in Clinical Practice

Portrait of Jonathan A. Ledermann
Prof. Jonathan A. Ledermann

Medical Oncologist

UCL Cancer Institute

United Kingdom (UK)

Portrait of Rebecca Dent
Dr Rebecca Dent

Medical Oncologist

National Cancer Center Singapore


Portrait of Robert L. Coleman
Dr Robert L. Coleman

Gynaecologic Oncologist

US Oncology Research

United States (US)

Portrait of Eric Pujade-Lauraine
Prof. Eric Pujade-Lauraine

Gynaecologic Oncologist

Hôpital Hôtel-Dieu


preview next

time E-learning | open 60 min |accreditation: EACCME | Sep 2021

This programme was made for you:   your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

DNA Damage Response (DDR) and PARP inhibitors are promising but complex therapeutic strategies.

Understand why, where and how PARP inhibitors work in clinical practice, and look into the future of targeting DDR with this interactive free to access e-learning course. Designed to support you in selecting the appropriate treatment strategy with PARP inhibitors in the appropriate patient population and to provide the best possible patient care.

This course is endorsed by the Innovative Breast Cancer Research Group (SOLTI), the Gynecological Cancer Group Singapore (GCGS) and the Gynecologic Oncology Trial and Investigation Consortium (GOTIC).

Downloadable slides accompany this e-learning for your own use.


This course has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) and ECMEC® is available. Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.

This educational programme is supported by an Independent Medical Education Grant from AstraZeneca

Other programmes of interest